Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Oxford-Harrington Rare Disease Centre (OHC) is a partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, established since 2019. The OHC aims to drive cutting-edge rare disease breakthroughs and in 2021 established a dedicated programme for recruiting leading disease area experts and co-ordinating substantial translational research efforts towards developing new treatments for Friedreich’s Ataxia (FA). 

Overview

The Oxford-Harrington Rare Disease Centre (OHC) is a partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals Cleveland, Ohio, established since 2019. The OHC aims to drive cutting-edge rare disease breakthroughs and in 2021 established a dedicated programme for recruiting leading disease area experts and co-ordinating substantial translational research efforts towards developing new treatments for Friedreich’s Ataxia (FA). Further information on the OHC and expertise in FA recruited can be found here.


FA is a debilitating, life-shortening, degenerative multi-system rare disease that affects roughly 1 in 50,000 people in the US/UK, with onset typically between 10-15 years of age. Individuals with FA have genetic mutations that result in a deficiency in the production of the protein frataxin, causing progressive damage and cell death in multiple organs and cell types. This leads to the symptoms of FA including difficulty walking, a loss of sensation and reflexes and cardiomyopathy. Despite extensive research there is no cure for FA, meaning that significant progress is still required to advance new therapeutics for patients in need.


The OHC FA programme is supported by the non-profit organisation EndFA, The Friedreich’s Ataxia Research Alliance (FARA), and Ataxia UK, and is collectively known as the Friedreich’s Ataxia Alliance at Oxford (FA Alliance). To turbocharge the OHC FA programme, the Translational Research Office (TRO, MSD) is pleased to announce a NEW translational funding opportunity targeting the development of new therapies to cure or treat FA. The FA Alliance Catalyst Fund has been established collaboratively between the TRO and OHC and will leverage co-funding from the TRO and recent philanthropic funding donated to the OHC FA programme.

REMIT

The FA Alliance Catalyst Fund supports proof-of-concept projects at the early stages of translation that are of high-risk but with potential of high reward. It will fund researchers to accelerate the transition from discovery research to translational development projects supporting preliminary work or feasibility studies to establish the viability of a translational approach.


The FA Alliance Catalyst Fund will initiate and accelerate cutting edge translational research currently underway within the OHC for development of a NEW treatment for FA and is exclusively available to Oxford’s researchers already tackling FA or working on a therapeutic platform intervention that could be applied in tackling FA. In exceptional circumstances, the panel will consider proposals that focus on another ataxia, repeat expansion diseases or a platform technology/approach where clear and direct relevance to FA is demonstrated.


This fund does NOT support:

  • exploratory basic science
  • research on biomarkers or devices unless they are directly linked to the therapeutic approach included in this application targeting FA
  • entire translational projects; bridging funding or PhD studentships
  • continuation of normal research grants
  • costs relating to protection of intellectual property.


Projects should aim to provide sufficient preliminary data to establish compelling proof-of-concept, strategic merit in a translational context, or the viability of a translational approach. An explicit outcome of the award is that projects should reach a value of inflection point as strong candidates to be considered for external follow-on translational funding and expertise through the Oxford-Harrington Rare Disease Scholar Award or Friedreich’s Ataxia Research Alliance funding opportunities.

FORMAT

It is envisaged that the available funds will finance up to THREE projects, with the TRO providing project management support for the funding scheme where appropriate. Awards will be co-funded with equal contributions from philanthropic funds and the TRO (Medical Research Council Impact Accelerator Account, MRC IAA).
Funding available from the FA Alliance Catalyst Fund will be up to £85k per project. Awards will be made from the FA Alliance Catalyst Fund for direct costs only.


Projects should be in the region of 6-12 months with funding for 12-month projects requiring full justification. Awards must commence within one month of the award letter being issued. All projects must be completed within one year of the start date and/or in line with overarching MRC grant conditions (TRO portion of funds contributing 50% to this funding scheme). Please ensure that your project is scheduled accordingly, and that the timeline is appropriate and realistic to the objectives and milestones set out.


Awards will be managed from the TRO on behalf of the University and the OHC. Applications, scores and reviewer comments may be shared with other internal University panels to ensure maximum value for money. Award conditions apply, including acceptance of a ‘mid-term’ review meeting with the TRO and a panel of experts to discuss progress made towards milestones, as well as commitment to providing yearly progress report return post completion.

ELIGIBILITY

Any researcher from the University of Oxford holding a contract extending to at least the end of the proposed project may apply, assuming they have host departmental approval. Applicants should clarify their eligibility with departments, and departmental approvers are required to check eligibility of their applicants before advancing any applications. The Committee welcomes applications from Early Career Researchers (ECRs). Early Career Researchers must have a contract extending to at least the end of the proposed project and must seek permission in writing from their direct line manager supporting the ECR to undertake the proposed work stated in the application. The ECR must also identify a mentor for the award period to support the delivery of the proposed work packages within the application as well as the proposed career development skills stated.

 

How to Apply

Applicants should complete an online application through IRAMS, which requests information about the principal applicant and any co-applicants, a lay summary (non-confidential – please see resources available on TRO website for writing a succinct and impactful lay summary), a financial breakdown of your proposal (X5 report must be appended) and a Case for Support Form uploaded to the IRAMS application system. You MUST incorporate all requested components of the Case for Support into ONE document (see below) and upload this in the template provided on IRAMS as a PDF.

Please note that applications must be reviewed and approved in IRAMS by a Departmental Approver before they will be reviewed by the Committee; the advertised application deadline is the deadline for final submission to the Reviewing Committee. Departments may set an earlier internal deadline to allow for departmental review, so please check with your local admin team and submit your application to your Departmental Approver in advance of the advertised deadline.

If you require an accessible version of any of the documents relating to this funding call, please contact translationalresearchoffice@medsci.ox.ac.uk.

A Case for Support Application Form (four pages max.) and CVs (one page max. for each PI & CoI) for all applicants named in the application must be appended to the IRAMS application form in addition to a comprehensive Gantt chart (one page max.). 

The Case for Support must include:

  • A 250-word abstract of the proposal requesting FA Alliance Catalyst Fund funding
  • Project objectives and proposed outcomes, including information about proposed development, milestones, and potential next steps following completion of the project and plans for commercialisation and clinical impact
  • A timeline for your project, aligning with milestones to demonstrate that these are realistic both in terms of the objectives set and the time necessary to achieve them; identification of ‘critical path’
  • A justification for support explaining how your proposal is aligned with the remit and objectives of the FA Alliance Catalyst Fund
  • Details of any industrial engagement in your project and plans to advance this; applicants with any relevant associations to University of Oxford spinouts must disclose all relevant information to the TRO in their Case for Support for governance review with appropriate conflict management in place
  • Intellectual property (IP) status: Are third parties involved and how will IP be managed with respect to these collaborators?
  • A description of any matched funding secured (not a requirement to apply)

Applicants are strongly advised to use the ‘Guidance for Applicants’ document on ‘What are the panel looking for?’ hints under each section of the Case for Support Form when completing your application.

KEY DATES AND DEADLINES

The FA Alliance Catalyst Fund will open for applications on Friday 24th January 2025.

The deadline for submission of FA Alliance Catalyst Fund applications via IRAMS is Wednesday 26th February 2025.

The panel meeting is anticipated to be held soon after the deadline [TBD]. Applicants will be notified by email of the outcome. Work must commence within one month of the award letter or otherwise agreed with the TRO.

 

REVIEWING GUIDELINES

Applications to the FA Alliance Catalyst Fund will be reviewed by a sub-committee of the TRO’s Medical and Life Sciences Translational Fund (MLSTF), chaired by Dr Nessa Carey and co-chaired by Professor Helen McShane. You can view the full list of committee members here. Please note the Committee membership comprises both internal academic and external commercial experts to ensure robust, rigorous review in line with funder recommendations.

Reviewers will follow the guidelines similar to the MLSTF scheme reviewing process. The details of how applications will be reviewed and scored is available here by scrolling down to the Reviewing Guidelines section. Please take time to familiarise yourself with these criteria and tailor your application accordingly.

 

FURTHER INFORMATION

All potential applicants are encouraged to discuss their proposals with the TRO (translationalresearchoffice@medsci.ox.ac.uk). If applicants wish to discuss the science of their proposal or applicability of an approach to FA, please contact Geoff Denwood at Geoffrey.Denwood@paediatrics.ox.ac.uk

The TRO can also assist with finding suitable collaborators and sourcing appropriate support and expertise through the Experts in Residence network.

Applicants are also encouraged to discuss their proposal with Oxford University Innovation (OUI) well in advance of submission. OUI will be able to advise and support on the industry engagement and IP strategy of the proposal. If you do not have an OUI contact, please contact the TRO who will be able to assist you.

For any further information regarding this Fund please contact: translationalresearchoffice@medsci.ox.ac.uk.

  • Opens: 24th January 2025
  • Deadline: 26th February 2025 12.00 pm UK time
  • Panel meeting: TBC

For enquiries about the call or to discuss your application please contact a member of the Translational Research Office.

CHAIR

Dr Nessa Carey, Entrepreneur in Residence (EiR), Medical Sciences Division

 

VICE-CHAIR


Professor Helen McShane, Professor of Vaccinology, Nuffield Department of Medicine

MEMBERS

TBD